LEVOFLOXACIN | N021571 | SANTEN INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Active | Kazakh Eye Research Institute | 90 | 2026-08-25 → 2026-11-20 | |
| Phase 2 | Active | Boston University | 271 | 2022-06-07 → 2027-05 | |
| N/A | Active | Turku University Hospital | 552 | 2017-04-03 → 2029-04-01 | |
| N/A | By Invitation | Turku University Hospital | 147 | 2017-08-09 → 2029-08-30 | |
| Phase 2/3 | Not Yet Recruiting | Copenhagen Respiratory Research | 460 | 2026-09-28 → 2029-09-01 | |
| N/A | Not Yet Recruiting | Assiut University | 93 | 2026-09-26 → 2028-02-25 | |
| Phase 2 | Not Yet Recruiting | University of Manitoba | 75 | 2026-09-01 → 2028-04-30 | |
| Phase 3 | Not Yet Recruiting | Seoul National University Hospital | 294 | 2026-10-01 → 2032-06 | |
| N/A | Not Yet Recruiting | The First Affiliated Hospital of Shihezi University | 350 | 2026-09-01 → 2027-12 | |
| N/A | Not Yet Recruiting | The First Affiliated Hospital of Shihezi University | 200 | 2026-11-01 → 2028-12 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
22 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 4, 2014 | SUPPL -6 | View Letter (PDF) |
| Mar 2, 2004 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.